Evidence map›Paper›PMID 36747128›Full record

ArticleBMC infectious diseases2023

Estimating the economic burden of respiratory syncytial virus infections in infants in Vietnam: a cohort study.

Lien Anh Ha Do, Elisabeth Vodicka, An Nguyen, Thi Ngoc Kim Le, Thi Thanh Hai Nguyen, Quang Tung Thai, Van Quang Pham, Thanh Uyen Pham, Thu Ngoc Nguyen, Kim Mulholland and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 4 countries.

Lien Anh Ha Do *New Vaccine Group, Murdoch Children's Research Institute, 50 Flemington Road, Parkville, Melbourne, 3051, Australia. lienanhha.do@mcri.edu.au.
Elisabeth Vodicka *PATH, Seattle, USA.
An NguyenPATH, Hanoi, Vietnam.
Thi Ngoc Kim LeChildren's Hospital 1, Ho Chi Minh City, Vietnam.
Thi Thanh Hai NguyenChildren's Hospital 1, Ho Chi Minh City, Vietnam.
Quang Tung ThaiChildren's Hospital 1, Ho Chi Minh City, Vietnam.
Van Quang PhamChildren's Hospital 1, Ho Chi Minh City, Vietnam.
Thanh Uyen PhamChildren's Hospital 1, Ho Chi Minh City, Vietnam.
Thu Ngoc NguyenPasteur Institute of Ho Chi Minh City, Ho Chi Minh City, Vietnam.
Kim MulhollandNew Vaccine Group, Murdoch Children's Research Institute, 50 Flemington Road, Parkville, Melbourne, 3051, Australia.
Minh Thang CaoPasteur Institute of Ho Chi Minh City, Ho Chi Minh City, Vietnam.
Nguyen Thanh Nhan LeChildren's Hospital 1, Ho Chi Minh City, Vietnam.
Anh Tuan TranChildren's Hospital 1, Ho Chi Minh City, Vietnam.
Clinton PecenkaPATH, Seattle, USA.
Children's Hospital 1 · VNInstitut Pasteur in Ho Chi Minh City · VNSeattle University · USLondon School of Hygiene & Tropical Medicine · GBThe University of Melbourne · AU

Funding

Gates Foundation INV-007610
6 · The paper itself

Abstract

backgroundLittle information is available on the costs of respiratory syncytial virus (RSV) in Vietnam or other low- and middle-income countries. Our study estimated the costs of LRTIs associated with RSV infection among children in southern Vietnam.

methodsWe conducted a prospective cohort study evaluating household and societal costs associated with LRTIs stratified by RSV status and severity among children under 2 years old who sought care at a major pediatric referral hospital in southern Vietnam. Enrollment periods were September 2019-December 2019, October 2020-June 2021 and October 2021-December 2021. RSV status was confirmed by a validated RT-PCR assay. RSV rapid detection antigen (RDA) test performance was also evaluated. Data on resource utilization, direct medical and non-medical costs, and indirect costs were collected from billing records and supplemented by patient-level questionnaires. All costs are reported in 2022 US dollars.

results536 children were enrolled in the study, with a median age of 7 months (interquartile range [IQR] 3-12). This included 210 (39.2%) children from the outpatient department, 318 children (59.3%) from the inpatient respiratory department (RD), and 8 children (1.5%) from the intensive care unit (ICU). Nearly 20% (105/536) were RSV positive: 3.9 percent (21/536) from the outpatient department, 15.7% (84/536) from the RD, and none from the ICU. The median total cost associated with LRTI per patient was US$52 (IQR 32-86) for outpatients and US$184 (IQR 109-287) for RD inpatients. For RSV-associated LRTIs, the median total cost per infection episode per patient was US$52 (IQR 32-85) for outpatients and US$165 (IQR 95-249) for RD inpatients. Total out-of-pocket costs of one non-ICU admission of RSV-associated LRTI ranged from 32%-70% of the monthly minimum wage per person (US$160) in Ho Chi Minh City. The sensitivity and the specificity of RSV RDA test were 88.2% (95% CI 63.6-98.5%) and 100% (95% CI 93.3-100%), respectively.

conclusionThese are the first data reporting the substantial economic burden of RSV-associated illness in young children in Vietnam. This study informs policymakers in planning health care resources and highlights the urgency of RSV disease prevention.

Indexed as

Respiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Tract InfectionsChildChild, PreschoolCohort StudiesFinancial StressHospitalizationHumansInfantProspective StudiesVietnamCost of illnessDirect costIndirect costLower respiratory tract infectionsRespiratory syncytial virus

Identifiers

PMID36747128
PMCPMC9901829
OpenAlexW4319312042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.